Johnson & Johnson - Investor Relations

News Releases

Johnson & Johnson Annual Meeting of Shareholders
April 25, 2013
10:00 AM ET

Johnson & Johnson First Quarter 2013 Earnings Meeting and Webcast
April 16, 2013
8:30 AM ET

View:

Year:

Search:

Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 |

All Releases
	FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet May 29, 2012	16.0 KB
	TITUSVILLE, N.J., May 29, 2012 -- Janssen Therapeutics, Division of Janssen Products, LP announced today the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter for a Supplemental New Drug Application (sNDA) for an 800mg tablet of PREZISTA® (darunavir). PREZISTA is approved for once-daily oral administration of ... Read more
	Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA^® (abiraterone acetate) Phase 3 Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting May 25, 2012	6.2 KB
	New Brunswick, NJ (May 25, 2012) -- Johnson & Johnson will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time, to coincide with the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Ill. Results from pre-specified interi... Read more
	FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO^® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome May 23, 2012	21.0 KB
	RARITAN, N.J., (May 23, 2012) -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted against the approval of XARELTO® (rivaroxa... Read more
	New Phase 3 Study Results Show Anti-Tnf Simponi^® Induced Clinical Response in Adults with Moderately to Severely Active Ulcerative Colitis May 21, 2012	20.3 KB
	San Diego, Calif., May 21, 2012 - New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI® (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were int... Read more
	Phase 3 Data Show NUCYNTA^® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) May 17, 2012	22.7 KB
	Raritan, N.J., May 17, 2012 -- Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral ... Read more
	Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome May 9, 2012	19.3 KB
	RARITAN, May 9, 2012 - Janssen Research & Development, LLC (Janssen) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO® (rivaroxaban), an oral anticoagulant, to reduce the risk of stent thrombosis in patients with ... Read more
	Johnson & Johnson to Participate in 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference May 2, 2012	5.8 KB
	NEW BRUNSWICK, N.J., May 2, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference on Wednesday, May 9, at The InterContinental Boston in Boston, MA. Dominic Caruso, Vice President, Finance & Chief Financial Officer will represent the Company in a session sc... Read more
	Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotech Co., Ltd. May 2, 2012	10.0 KB
	GUANGZHOU, China (May 2, 2012) - Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotech Co., Ltd. (Bioseal), a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery... Read more
	Janssen Research & Development Submits XARELTO^® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism May 2, 2012	18.0 KB
	RARITAN, May 2, 2012 - Janssen Research & Development, LLC, (Janssen), announced today that it has submitted supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO® (rivaroxaban), an oral anticoagulant, to treat patients with deep vein thrombosis (DVT) or p... Read more
	Johnson & Johnson Holds 2012 Annual Meeting of Shareholders Apr 26, 2012	12.9 KB
	NEW BRUNSWICK, N.J., April 26, 2012 /PRNewswire/ -- After 10 years presiding over Johnson & Johnson (NYSE: JNJ) during a period of extraordinary change in the health care industry, Chairman and Chief Executive Officer Bill Weldon officially transferred responsibilities for running the company to incoming CEO Alex Gorsky at the Annual Meeting of Sha... Read more
	Johnson & Johnson Announces Dividend Increase of 7.0% Apr 26, 2012	7.9 KB
	NEW BRUNSWICK, N.J., April 26, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.0% increase in the quarterly dividend rate, from $0.57 per share to $0.61 per share. The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, NJ. "In recognitio... Read more
	Johnson & Johnson to Webcast Annual Meeting of Shareholders Apr 19, 2012	5.8 KB
	New Brunswick, N.J. (April 19, 2012) -- Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 26, 2012, from the Hyatt Regency Hotel in New Brunswick, N.J. Investors and other interested parties may access the live webcast of the meeting by visiting the Company's we... Read more
	Johnson & Johnson Reports 2012 First-Quarter Results: Apr 17, 2012	46.1 KB
	NEW BRUNSWICK, N.J., April 17, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $16.1 billion for the first quarter of 2012, a decrease of 0.2% as compared to the first quarter of 2011. Operational results increased 1.0% and the negative impact of currency was 1.2%. Domestic sales declined 5.1%. International... Read more
	Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results Apr 10, 2012	6.0 KB
	NEW BRUNSWICK, N.J., April 10, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, April 17th, to review first-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President, Investor Relations, will ... Read more
	Johnson & Johnson Announces Resignation of Sheri S. McCoy Apr 9, 2012	6.6 KB
	NEW BRUNSWICK, N.J., April 9, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) said today that Sheri S. McCoy, Vice Chairman of the Executive Committee, has resigned from the Company effective April 18 to join another publicly traded company as CEO. Ms. McCoy joined Johnson & Johnson in 1982 and was appointed to her current responsibilities in J... Read more
	Ortho-Clinical Diagnostics, Inc. Announces Availability of HTLV-I/II Assay Mar 28, 2012	10.9 KB
	RARITAN, NJ -- (Marketwire) -- 03/28/12 -- Ortho Clinical Diagnostics, Inc. (OCD) today announced the availability of the Avioq® HTLV-I/II Microelisa System assay, a new test developed in partnership with Avioq, Inc. to screen blood and organ donations for antibodies to human T-lymphotropic virus (HTLV) type I and II. Screening for antibo... Read more
	FDA Approves INTELENCE^® (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1, Following Priority Review Mar 27, 2012	15.9 KB
	[Titusville, NJ, March 27, 2012] - Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved INTELENCE® (etravirine) to be administered in combination with other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in treatment-exper... Read more
	XARELTO® (rivaroxaban) Demonstrates Comparable Efficacy to Standard of Care for the Treatment and Secondary Prevention of Venous Blood Clots in Patients with Symptomatic Pulmonary Embolism in Pivotal Phase 3 Study Mar 26, 2012	26.2 KB
	CHICAGO, March 26, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen), announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO® (rivaroxaban) was comparable to today's standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary... Read more
	Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiology's Annual Scientific Sessions Mar 19, 2012	6.3 KB
	NEW BRUNSWICK, N.J., March 19, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Monday, March 26th at approximately 10:30 a.m., Eastern Time, to coincide with the American College of Cardiology (ACC) Annual Scientific Sessions in Chicago, Ill. Phase 3 resul... Read more
	Study Unblinded: ZYTIGA^® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Mar 8, 2012	60.1 KB
	RARITAN, NJ, March 8, 2012 - Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA® (abiraterone acetate) plus prednisone for the treatment of asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who have not received chemotherapy. ... Read more

= add release to Briefcase